These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 38184909

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of Ublituximab compared to Teriflunomide for relapsing multiple sclerosis: A meta-analysis.
    Mukhtar H, Yasmeen U, Siddiqa S, Sarfraz Z, Sarfraz A.
    Mult Scler Relat Disord; 2022 Sep; 65():104002. PubMed ID: 35779372
    [Abstract] [Full Text] [Related]

  • 7. Real-world experience of teriflunomide in relapsing multiple sclerosis: paramagnetic rim lesions may play a role.
    Tan H, Li X, Li Y, He F, ZhangBao J, Zhou L, Yang L, Zhao C, Lu C, Dong Q, Li H, Quan C.
    Front Immunol; 2024 Sep; 15():1343531. PubMed ID: 38558796
    [Abstract] [Full Text] [Related]

  • 8. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC, ULTIMATE I and ULTIMATE II Investigators.
    N Engl J Med; 2022 Aug 25; 387(8):704-714. PubMed ID: 36001711
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of teriflunomide in Asian patients with relapsing forms of multiple sclerosis: A subgroup analysis of the phase 3 TOWER study.
    Miller AE, Xu X, Macdonell R, Vucic S, Truffinet P, Benamor M, Thangavelu K, Freedman MS.
    J Clin Neurosci; 2019 Jan 25; 59():229-231. PubMed ID: 30348586
    [Abstract] [Full Text] [Related]

  • 10. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T, Banwell B, Kappos L, Arnold DL, Gücüyener K, Deiva K, Skripchenko N, Cui LY, Saubadu S, Hu W, Benamor M, Le-Halpere A, Truffinet P, Tardieu M, TERIKIDS Investigators.
    Lancet Neurol; 2021 Dec 25; 20(12):1001-1011. PubMed ID: 34800398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.
    Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L.
    J Neurol; 2022 Sep 25; 269(9):4808-4816. PubMed ID: 35403875
    [Abstract] [Full Text] [Related]

  • 13. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK, Frederiksen JL, Nielsen HH, Torkildsen Ø, Eek C, Huang-Link Y, Haghighi S, Tsai JA, Kant M.
    Mult Scler Relat Disord; 2022 Jul 25; 63():103892. PubMed ID: 35696880
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Matching-adjusted indirect treatment comparison of ozanimod versus teriflunomide for relapsing multiple sclerosis.
    Cohan S, Tencer T, Arndorfer S, Zhu X, Zivkovic M, Kumar J.
    Mult Scler Relat Disord; 2021 Jul 25; 52():102972. PubMed ID: 33979770
    [Abstract] [Full Text] [Related]

  • 16. Serum teriflunomide concentrations in routine multiple sclerosis therapy: A cross-sectional pilot study.
    Kusnirikova ZK, Kacirova I, Pesakova V, Hradilek P, Brozmanova H, Grundmann M.
    J Neurol Sci; 2024 Mar 15; 458():122910. PubMed ID: 38309248
    [Abstract] [Full Text] [Related]

  • 17. An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
    Valenzuela B, Olsson Gisleskog P, Poggesi I, Sidorenko T, Burcklen M, Kracker H, Pérez-Ruixo JJ.
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct 15; 11(10):1294-1304. PubMed ID: 36047474
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
    Miller AE, Olsson TP, Wolinsky JS, Comi G, Kappos L, Hu X, Xu X, Lublin AL, Truffinet P, Chavin J, Delhay JL, Benamor M, Purvis A, Freedman MS, TOWER investigators.
    Mult Scler Relat Disord; 2020 Nov 15; 46():102438. PubMed ID: 32911306
    [Abstract] [Full Text] [Related]

  • 19. Lymphocytic colitis in the setting of teriflunomide use for relapsing multiple sclerosis.
    Son M, McEwan L, Ubaidat M, Bovell K, Morrow SA.
    Mult Scler; 2020 Nov 15; 26(13):1801-1803. PubMed ID: 32031458
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.